Psoriasis is one of the most common chronic recurrent multifactorial diseases of the skin with a predominance of genetic predisposition. The disease is characterized by hyperproliferation of epidermal cells, impairment of the keratinisation against the background of inflammatory reactions in the dermal layer, the nails, joints and scalp involvement. According to the results of clinical and epidemiological research, about 3-4% of the population of our planet has psoriasis, regardless of sex, age and ethnic group, while the share of this pathology in the overall structure of skin diseases reaches from 1% - to 40%, according to some reports. However, despite the wide prevalence of psoriasis and a huge number of works on this issue, there is still no shared view on the pathogenesis of this dermatosis. The data presented by many clinical studies show that there has been a recent increase in cases of comorbidity of psoriasis and obesity, leading to severe, atypical, disabling and resistant to the treatment forms of dermatosis. All this considerably impairs the quality of life of patients with psoriasis, reduces their working capacity and social activity that lays emphasis on not only the medical but also the social significance of the problem. Immunological disorders and genetic defects have been proven as the causes of psoriasis and abdominal obesity. The distinctive feature of the pathogenesis in the patients having comorbidity of psoriasis and obesity, in contrast to the patients without excessive body weight, is a statistically significant increase in hyperleptinomia and in systemic cytokine proinflammatory potential. Therefore, the vision for the future research is in-depth study of the pathogenesis of comorbid disease in patients with psoriasis that will contribute to reveal new targets for the treatment of this dermatosis.